Gene Therapy Q1 Roundup: The Struggle Is Real

 
• By Jessica Merrill

Vertex and bluebird compete for sickle cell patients, BioMarin talks about divesting Roctavian, and Sarepta warned that sales of Elevidys will plateau with a narrow label.  

turtle
Gene therapies are making slow progress commercially • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies